BEIJING–(BUSINESS WIRE)–Genetron Holdings Limited (�Genetron Health or the Company, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will host virtual investor meetings at the 24th Credit Suisse Asian Investment Conference on Mar. 26th, 2021.
Sizhen Wang, co-founder and Chief Executive Officer, will also attend a fireside chat at 3:00 pm Beijing time (3:00 am ET).
Interested parties may request more information by contacting their sales representative at Credit Suisse.
About Genetron Holdings Limited
Genetron Holdings Limited (Genetron Health or the Company) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Companys beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as may, will, expect, anticipate, target, aim, estimate, intend, plan, believe, potential, continue, is/are likely to or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Companys filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
Contacts
Investor Relations
US:
Hoki Luk
Head of Investor Relations
Email: hluk@genetronhealth.us
Phone: +1 (408) 891-9255
David Deuchler, CFA
Managing Director | Gilmartin Group
Email: David@gilmartinir.com
Phone: (917) 209-5605
ADEPIDYN® technology on track to be first of Syngenta's crop protection active ingredients to attain…
The developer is now the largest single owner of LEED Platinum grade office buildings in…
PARIS--(BUSINESS WIRE)--Regulatory News: On the occasion of the state visit to France by the President…
A breakthrough approach and supporting data using epigenome editing technology for the treatment of a…
TAIPEI, Taiwan--(BUSINESS WIRE)--United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) (“UMC”), today reported unaudited net sales…
Conversion of 14 hotels marks Marriott International’s debut of affordable midscale segment in Asia Pacific…